Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: The present invention relates to a novel monoclonal antibody which is specifically bound to a transmembrane 4 L six family member 5 (TM4SF5) protein. More particularly, the present invention relates to a monoclonal antibody which is specifically bound to a human TM4SF5 protein, to polynucleotides coding for the monoclonal antibody, to an expression vector comprising the nucleotides, to a transformant with the vector introduced thereto, to a method for preparing the monoclonal antibody, to a composition comprising the monoclonal antibody, to a method for treating liver fibrosis using the monoclonal antibody, to a method for treating cancer using the monoclonal antibody, to a method for inhibiting metastasis of cancer, to a method for diagnosing cancer using the monoclonal antibody and to a cancer diagnosis kit comprising the monoclonal antibody.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating cancer or inflammatory disease, containing an NDRG3 expression or activity inhibitor as an active ingredient. Furthermore, the present invention relates to an NDRG3 protein-specific antibody and a use thereof. Specifically, the antibody to the NDRG3 protein is prepared, and the antibody is used to verify that NDRG3 mediated by lactate generated from a hypoxia reaction promotes cell proliferation, angiogenesis, and cytokine expression through the lactate-NDRG3-c-Raf-ERK signaling pathway, and thus the antibody binding to the epitope of the NDRG3 or a fragment of the antibody can be favorably used in the research of cancer or inflammation occurrence mechanism, the development of novel genes involved in the mechanism, and the development of therapeutic agents and new pharmaceuticals.

Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.

Abstract: A method of detecting and quantifying various enzymatic activities using a constructed artificial genetic circuit GESS (genetic enzyme screening system) for sensing phenolic compounds and a method of screening a trace of activities of target enzymes from a metagenome using the artificial genetic circuit, thereby securing target enzyme genes. When the method for screening and quantifying target enzymatic activity is used, useful genes can be screened from various genetic communities, including environmental or metagenomic libraries, at a single cell level in high throughput (million/day). Further, the sensitivity of the genetic circuit to phenol derivatives and the expression thereof can be controlled, and thus the genetic circuit can rapidly sense and quantify various enzymatic activities. Thus, the method can be advantageously used in the protein engineering technology for enzyme modification.

Abstract: The present invention relates to a method of eliciting plant immune responses based on seed priming by using the heat (high temperature)-treated culture solution of Bacillus spp, and the high pressure-sterilized culture solution of Bacillus sp. strains PB69 and 1628 which have been selected in the present invention exhibits an activity of eliciting induced systemic resistance similar to BTH, and also has an effect for inducing promoted plant growth and controlling plant diseases, and thus it is expected to contribute to enhance the crop productivity.

Abstract: The present invention relates to a method for producing astrocytes comprising obtaining neural progenitor cells from stem cells so as to continuously produce astrocytes with high purity and same traits, followed by two steps of differentiating the neural progenitor cells into the astrocytes, and astrocytes produced therefrom. Since the method of preparing the astrocytes provided in the present invention enables not only production of the astrocytes with high purity and faster production of the astrocytes with same characteristics, but also rapid differentiation of the astrocytes using the neural progenitor cells when necessary, it can be widely used for effectively treating a patient with a disease which requires transplantation of the astrocytes.

Abstract: The present invention relates to a method for producing cholinergic neurons comprising obtaining neural progenitor cells from stem cells so as to continuously produce cholinergic neural cells with high purity and the same traits, followed by differentiating the neural progenitor cells into the cholinergic neurons, and cholinergic neurons produced therefrom. Since the method of preparing the cholinergic neurons provided in the present invention enables not only production of the cholinergic neurons with high purity, but also rapid production of the cholinergic neurons with the same traits, it can be widely used for effectively treating degenerative cranial nerve diseases such as Alzheimer's disease.

Abstract: As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer.

Abstract: The present invention relates to a composition for detecting the undifferentiated human pluripotent stem cells comprising an agent useful for measuring the level of Desmoglein 2 (Dsg 2) mRNA or the protein thereof, a kit for detecting the undifferentiated human pluripotent stem cells comprising the said composition, a method for detecting the undifferentiated human pluripotent stem cells containing the step of measuring the level of Desmoglein 2 mRNA or the protein thereof, a method for evaluating the differentiation of human pluripotent stem cells and thereafter for separating the undifferentiated human pluripotent stem cells, a method for reducing the undifferentiated status of human pluripotent stem cells by inhibiting the expression or activation of Desmoglein 2, and a monoclonal antibody binding specifically to human Desmoglein 2.

Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

Abstract: The present invention relates to a modified TXNIP protein, a method for preparing the modified TXNIP protein, a polynucleotide encoding the modified protein, an expression vector including the polynucleotide, a transformant introduced with the expression vector, a method for crystallizing a modified TRX-TXNIP complex using the modified TXNIP protein, and a method for screening a substance regulating interaction between TRX and TXNIP, an inhibitor of TRX activity, or a substance regulating TXNIP function.

Abstract: The present invention relates to a new gene fragment derived from Chinese hamster ovary (CHO) cell for enhancement of recombinant protein expression in animal cells and a use thereof. It has been found that using the vector comprising a gene fragment of the present invention enhances the expression of a target protein in animal cells. Accordingly, the vector comprising a gene fragment of the present invention could be usefully used in the production of biopharmaceuticals such as therapeutic antibodies, etc.

Abstract: The present invention relates to: coralmycin A and B, which are novel compounds exhibiting antimicrobial activity, an isomer thereof, a derivative thereof or a pharmaceutically acceptable salt thereof; a microorganism of the genus Corallococcus producing the same; and an antimicrobial use thereof. The coralmycin A and B have very strong antimicrobial activity against antibiotic-resistant bacteria such as MRSA, QRSA, VRE, VISA, etc.; Acinetobacter baumannii, which is a multidrug-resistant microorganism; and also against gram-positive microorganisms and gram-negative microorganisms. Therefore, the present invention can be very useful for prevention, treatment and alleviation of various microbial infections, and thus can be widely applied to the medical supply, quasi-drug, food, and feed industries.

Abstract: The present invention relates to a method for analyzing the interaction between a binding protein and a target material, including measuring the interaction between the binding protein and a target material using an interaction trapper (IT) cell. The IT cell has the binding protein displayed on the surface of intracellular inclusion bodies, i.e., insoluble aggregates, by expressing a fusion protein which forms active protein particles containing the binding protein. The method includes increasing cell permeability without affecting the activity of the binding protein displayed on the cells and genetic information.

Abstract: The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

Abstract: The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical composition for preventing or treating viral diseases as well as a health functional food, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.

Abstract: The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

Abstract: A method comprising transforming Schizosaccharomyces pombe with a deletion cassette, constructed by four-round serial PCR, block PCR or total gene synthesis, containing a homologous recombination site is provided for preparing gene-targeted heterozygous deletion Schizosaccharomyces pombe. Also provided are gene-targeted hetero2ygous deletion Schizosaccharomyces pombe mutants prepared by the method, and a library of gene-targeted heterozygous deletion Schizosaccharomyces pombe mutants. Further, the library is useful in constructing a method and a kit for screening a drug's modes of action.

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).